Charles River Laboratories EBITDA 2010-2025 | CRL

Charles River Laboratories EBITDA for the quarter ending March 31, 2025 was $0.195B, a 7.71% decline year-over-year.

  • Charles River Laboratories 2024 EBITDA was 0.804B, a 13.67% decline from 2023.
  • Charles River Laboratories 2023 EBITDA was 0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 EBITDA was 0.955B, a 11.63% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Charles River Laboratories EBITDA 2010-2025 | CRL

  • Charles River Laboratories 2024 EBITDA was 0.804B, a 13.67% decline from 2023.
  • Charles River Laboratories 2023 EBITDA was 0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 EBITDA was 0.955B, a 11.63% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$133.5B
Elevance Health (ELV)$96.1B
CVS Health (CVS)$84.8B
Cencora (COR)$55.6B
DiDi Global (DIDIY)$20.3B
Natera (NTRA)$20B
BioMerieux (BMXMF)$15.6B
Solventum (SOLV)$11.5B
ICON (ICLR)$11.3B
EUROFINS SCIENT (ERFSF)$11.1B
Revvity (RVTY)$11B
CochLear (CHEOY)$10.9B
Avantor (AVTR)$10.3B
Doximity (DOCS)$9.9B
Viatris (VTRS)$9B
Medpace Holdings (MEDP)$9B
Sonic Healthcare (SKHHY)$7.7B
HealthEquity (HQY)$7.3B
Amplifon S.p.A (AMFPF)$4.3B
Bausch + Lomb (BLCO)$4.3B
Alignment Healthcare (ALHC)$3.5B
Sotera Health (SHC)$3B
BrightSpring Health Services (BTSG)$2.9B
Organon (OGN)$2.9B
Surgery Partners (SGRY)$2.7B
GeneDx Holdings (WGS)$2.7B
Concentras Parent (CON)$2.6B
Progyny (PGNY)$1.8B
Ardent Health Partners (ARDT)$1.8B
Premier (PINC)$1.8B